Skip to main content
OpenTrials
Completed

NCT Number: NCT02413814

Computerized Anger-Reduction Treatment for Smoking Cessation

Problematic anger is a strong predictor of failed attempts at smoking cessation. The investigators proposed study seeks to evaluate whether a novel 8-session computerized anger-reduction treatment improves quit rates among smokers. Smokers with elevated trait anger will be administered transdermal nicotine patch therapy and either anger-reduction treatment or a control intervention. They will be assessed throughout treatment and up until three months after a scheduled mid- treatment quit date. The investigators propose to test whether, compared to the control condition, the anger-reduction treatment will lead to: 1) greater reductions in anger and 2) greater abstinence rates at post-cessation and at follow-up assessments. The investigators will also test whether changes in anger-related symptoms account for group differences in abstinence rates.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Florida State University, Department of Psychology

Tallahassee, Florida, 32306, United States

About this study

The current proposal seeks to evaluate an eight-session, computerized, anger-focused intervention for smokers (Anger Reduction Treatment or ART). The investigators will administer this intervention to smokers (N = 114) who are interested in quitting and have elevated levels of trait anger. Participants will be randomly assigned to receive either: (1) computerized ART, consisting of interpretation bias modification, or (2) a computerized control condition, which consists of health education and relaxing video clips. The computerized sessions (eight total) will take place twice a week for four weeks. All participants will have a scheduled quit date for the beginning of the third week of treatment (i.e., at mid-treatment). All participants will also receive nicotine patch therapy to use at their scheduled quit date. Anger symptoms, smoking cravings, and smoking frequency will be assessed throughout treatment. Smoking status, anger, and other measures of negative affect will also be assessed at baseline and regularly for 12-weeks following the scheduled quit date.

The investigators will test whether, compared to the control condition, the anger-reduction treatment will lead to: 1) greater reductions in anger and 2) greater abstinence rates at post-cessation and at follow-up assessments. The investigators will also test whether changes in anger-related symptoms account for group differences in abstinence rates.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Elevated levels of trait anger (scoring 22 or higher on the STAXI-trait)
  • Currently smoking an average of 8 cigarettes per day
  • Must be a regular (daily) smoker for at least 1 year
  • Willing to make a serious attempt to quit smoking
  • Must report motivation to quit in the next month (30 days) of at least 5 on a 10 point scale (0 = no motivation and 10 = extreme motivation)
  • Have not decreased the number of cigarettes by more than half in the past six months
  • Must be an English speaker

Exclusion criteria

  • Current substance dependence (excluding nicotine dependence)
  • Current use of other tobacco products
  • Currently receiving cognitive therapy or therapy for problematic anger
  • Evidence of serious suicidal intent requiring hospitalization or immediate treatment
  • Limited mental competency and the inability to give informed, written consent
  • Evidence of psychotic-spectrum disorders
  • Changes in medication over the last month

Treatment and study plan

Anger Reduction Treatment

Behavioral

Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.

Control condition

Behavioral

Eight 30-minute sessions of informative videos on healthy living and relaxation videos.

Primary outcomes

  1. State-Trait Anger Expression Inventory-2 (STAXI-2; Spielberger, 1999) state and trait subscales

    Time frame: up to 14-weeks following treatment initiation.

  2. Self-reported smoking frequency

    Time frame: up to 14-weeks following treatment initiation.

  3. Carbon monoxide levels

    Time frame: up to 14-weeks following treatment initiation.

Secondary outcomes

  1. Minnesota Nicotine Withdrawal Scale (Hughes & Hatsukami, 1986)

    Time frame: up to 14-weeks following treatment initiation.

  2. Beck Depression Inventory-II (Beck, Steer, & Brown, 1996)

    Time frame: Baseline and regularly for 14-weeks following treatment initiation.

  3. Clinical Anger Scale (CAS; Snell, Gum, Shuck, Mosley, & Hite, 1995)

    Time frame: up to 14-weeks following treatment initiation.

  4. WSAP-Hostility Scale (Dillon, Cougle, & Fincham, 2015)

    Time frame: up to 14-weeks following treatment initiation.

  5. Hostile Automatic Thoughts Scale (Snyder, Crowson, Houston, Kurylo, & Piorier, 1997)

    Time frame: up to 14-weeks following treatment initiation

  6. Questionnaire of Smoking Urges (Tiffany & Drobes, 1991)

    Time frame: up to 14-weeks following treatment initiation.

Sponsors and collaborators

Lead sponsor

Florida State University

Other

Registry information

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Apr 10, 2015
Registry last updated
Jan 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.